首页 › 期刊 › 医学 › Journal of Thoracic Oncology
Journal of Thoracic Oncology
出版商:Elsevier · ISSN:1556-0864, 1556-1380 · 国家/地区:US · 类型:journal · 创刊:2006-00-00 · 官网:https://www.journals.elsevier.com/journal-of-thoracic-oncolo...
研究主题:Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Lung Cancer Research Studies · Cancer Immunotherapy and Biomarkers · Radiomics and Machine Learning in Medical Imaging
核心指标
- 影响因子(JCR 2024):20.800
- JCR 分区:Q1(ONCOLOGY(SCIE);RESPIRATORY SYSTEM(SCIE))
- 中科院分区(2025):医学 1区(Top);小类:ONCOLOGY 肿瘤学 1区
- 新锐分区(2026):医学 1区
- SJR:7,497(Q1)
- h-index:222
- i10 指数:4444
- 近两年篇均被引:1.01
- 载文量 28386 · 总被引 355820
逐年趋势
- 近年影响因子:2020 15.6 → 2021 20.1 → 2022 20.4 → 2023 21 → 2024 20.8
- 近年 SJR:2021 4.74(Q1) → 2022 5.87(Q1) → 2023 7.88(Q1) → 2024 7.95(Q1) → 2025 7.5(Q1)
投稿参考
- 版面费(APC)约 $4000 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
- 提供投稿指南
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Journal of Thoracic Oncology》的影响因子是多少?
根据 JCR 2024 年数据,《Journal of Thoracic Oncology》的最新影响因子(IF)为 20.800。
《Journal of Thoracic Oncology》是几区期刊?
《Journal of Thoracic Oncology》中科院分区(2025年版)为医学1区(Top 期刊),JCR 分区为 Q1。
《Journal of Thoracic Oncology》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《Journal of Thoracic Oncology》的文章处理费(APC)约为 $4000 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials (2026 · 被引 6)
- Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort (2026 · 被引 3)
- Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group (2026 · 被引 2)
- First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis (2026 · 被引 1)
- Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report (2026)
- PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study (2026)